Question 1

What is CDMO regulatory submission software?

Accepted Answer

CDMO regulatory submission software supports the CMC documentation work that contract development and manufacturing organizations deliver to sponsor pharma/biotech companies. It handles Module 3 (Quality) content authoring, analytical method documentation, stability data summaries, process descriptions, and the sponsor handoff workflow. Unlike sponsor-facing software, CDMO software is oriented around multi-sponsor delivery with strict data isolation between sponsor programs, shared analytical and process libraries across programs, and sponsor-facing review workflows.

Question 2

How does Assyro handle multi-sponsor data isolation for CDMOs?

Accepted Answer

Each sponsor program runs in an isolated workspace with separate document storage, separate access controls, and separate audit trails. CDMO staff can work across multiple sponsors but the data boundaries are platform-enforced. This matters because sponsors often have confidentiality clauses that require the CDMO to demonstrate technical isolation of their data from other sponsors, especially for innovative therapeutics where manufacturing know-how is competitively sensitive.

Question 3

Can CDMOs reuse analytical methods across sponsors?

Accepted Answer

Yes, where contractually permitted. Many analytical methods (USP assays, ICH Q6 monographs, pharmacopeia methods) are public and fully shareable across sponsor programs. CDMO-developed proprietary methods or methods developed for a specific sponsor are scoped appropriately. Assyro's method library structure preserves the sharing-vs-isolation distinction: public methods propagate across programs, sponsor-specific methods stay in the sponsor's workspace. This eliminates the rewriting of the same standard method description for every sponsor.

Question 4

What Module 3 content does Assyro support?

Accepted Answer

Full Module 3 (Quality) coverage: 3.2.S (Drug Substance) including manufacture, characterization, specifications, analytical methods, stability; 3.2.P (Drug Product) including manufacture, composition, development, specifications, stability; 3.2.A (Appendices) including facilities, equipment, adventitious agents safety; and 3.2.R (Regional Information) for region-specific quality requirements. Module 3 is the most structurally demanding module and is where most CDMO-sponsor handoff friction happens.

Question 5

How does Assyro compare to Veeva QualityOne for CDMOs?

Accepted Answer

Veeva QualityOne is a quality management system with CDMO-specific modules for batch records, deviations, CAPA, and supplier management. Assyro is regulatory-submission-first. Most CDMOs need both: QualityOne (or equivalent) for shop-floor GMP operations, and submission software for the documentation that becomes part of sponsor filings. The two complement rather than compete. Some CDMOs adopt Assyro specifically for the submission/sponsor-handoff workflow while keeping their existing QMS for operational quality.

Question 6

Does Assyro support PAI (Pre-Approval Inspection) readiness?

Accepted Answer

Yes, adjacent to the submission workflow. PAI readiness is about operational GMP evidence (batch records, deviations, process validation, equipment qualification) more than submission content, but the submission's Module 3 is what FDA uses to scope and focus the inspection. Assyro keeps the submission-to-operational-evidence linkage clear: when FDA plans a PAI based on Module 3.2.P.3 process information, the linked operational evidence is retrievable for the PAI team. This reduces the scramble that CDMOs typically run during PAI scheduling.

Question 7

How do sponsors review CDMO-contributed content?

Accepted Answer

Sponsors get scoped review access to their assigned sections with the same tracked-change workflow that the CDMO uses internally. Review comments flow back to the CDMO section owner, revisions happen in-place, and approval gates the move to sponsor-final status. This replaces the email-and-attachment review pattern that still dominates CDMO-sponsor relationships. Review cycles that take 2-3 weeks in the traditional workflow typically compress to 3-5 days in Assyro.

Question 8

Does Assyro work for biologics and cell/gene therapy CDMOs?

Accepted Answer

Yes. Biologics CDMOs (recombinant proteins, monoclonal antibodies, vaccines) and cell/gene therapy CDMOs have additional Module 3 content requirements beyond small-molecule: more extensive characterization, adventitious agents safety, comparability across process changes, and for cell/gene therapy, the CBER-specific CMC considerations. Assyro's Module 3 structure accommodates biologic and CGT-specific content, with authoring templates aligned to ICH Q5A-Q5E and CBER guidance. The sponsor-facing workflow is the same; the content-specific requirements differ.

CDMO Regulatory Submission Software

CDMOs Submission Workflow

Deliver Module 3 Content That Sponsors Don't Send Back

Give Multiple Sponsors Controlled Access to Their Own Sections

Stop Retyping the Same Analytical Method Description 12 Times

Keep the GMP Audit Trail Your Sponsor's QA Team Can Defend

CDMOs Workflow Controls at Scale

Maintain Audit-Ready Submission Workflows

Manage More CDMOs Programs With the Same Team Size

Questions About CDMOs Workflows

See CDMOs Submission Workflows in Assyro.